November 2nd, 2018 | Nagesh K. Mahanthappa, PhD, MBA

Without a doubt, recent advances in immunotherapy have transformed the treatment of patients with cancer. Many patients with previously intractable cancers are now stabilized or have even had their cancer rendered undetectable. The astounding results seen with checkpoint blockade therapies (CBTs), particularly anti-PD1/PDL1 antibodies, have now established these medicines as a mainstay in cancer treatment, […]

CONTACT  |  SITEMAP  | 
 |  SITE DESIGN
“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2018 Scholar Rock All Rights Reserved.
Back to Top
 

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel